Login to Your Account

Uniqure jumps on early gene therapy data in hemophilia B patients

By Nuala Moran
Staff Writer

Thursday, January 7, 2016

LONDON – Uniqure NV reported that four of five patients suffering from severe or moderately severe hemophilia B have been able to discontinue prophylaxis with recombinant factor IX.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription